High DPP-4 Concentrations in Adolescents Are Associated With Low Intact GLP-1

The Journal of Clinical Endocrinology and Metabolism
Rasmus StenlidAnders Forslund

Abstract

Dipeptidyl peptidase 4 (DPP-4) metabolizes glucagon-like peptide-1 (GLP-1), and increased DPP4 levels are associated with obesity and visceral adiposity in adults. Investigating DPP-4 levels in adolescents and their association with (1) circulating intact GLP-1 levels and glucose tolerance; (2) body mass index (BMI); and (3) visceral, subcutaneous, and liver fat compartments. Cross-sectional study, July 2012 to April 2015. Pediatric obesity clinic, Uppsala University Hospital. Children and adolescents with obesity (n = 59) and lean controls (n = 21) aged 8 to 18 years. BMI SD score, fasting plasma concentrations of DPP-4, total and intact GLP-1, fasting and oral glucose tolerance test (OGTT) concentrations of glucose, and visceral adipose tissue (VAT) and subcutaneous adipose tissue volumes and liver fat fraction. Plasma DPP-4 levels decreased with age in both obese (41 ng/mL per year) and lean subjects (48 ng/mL per year). Plasma DPP-4 levels were higher in males in both the obesity and lean groups. With adjustments for age and sex, plasma DPP-4 level was negatively associated with intact GLP-1 at fasting (β = -12.3; 95% CI: -22.9, -1.8) and during OGTT (β = -12.1; 95% CI: -22.5, -1.7). No associations were found between DPP-4...Continue Reading

References

Apr 12, 2002·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Richard S Shames
Aug 2, 2003·Critical Reviews in Clinical Laboratory Sciences·Anne-Marie LambeirIngrid De Meester
Mar 6, 2004·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·R LugariR Zandomeneghi
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Jun 27, 2009·Cancer Immunology, Immunotherapy : CII·Oscar J CorderoMontserrat Nogueira
Dec 23, 2011·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Johan Berglund, Joel Kullberg
May 23, 2012·Clinical Therapeutics·Vanita R ArodaByron J Hoogwerf
Jan 15, 2014·Pediatrics·Anders ForslundPeter Bergsten
Sep 13, 2014·Endocrine Reviews·Erin E Mulvihill, Daniel J Drucker
Jan 9, 2016·The Journal of Clinical Endocrinology and Metabolism·Hannes ManellPeter Bergsten
Jan 23, 2016·Clinical Biochemistry·Eduardo Ottobelli ChielleMaria Beatriz Moretto
Feb 27, 2016·Clinical and Experimental Immunology·C KlemannS von Hörsten
Mar 5, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Aline BeckenkampAndréia Buffon
Jun 21, 2016·Diabetes Research and Clinical Practice·Sayuri TanakaToshitsugu Sugimoto

❮ Previous
Next ❯

Citations

Oct 28, 2019·Current Opinion in Allergy and Clinical Immunology·Ida MogensenAndrei Malinovschi
Dec 12, 2019·The Journal of Clinical Endocrinology and Metabolism·Victoria HigginsKhosrow Adeli
Dec 21, 2019·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Chengcong ChenZiqiong Zhou
Aug 27, 2021·Clinical and Translational Science·Rasmus StenlidMaria Halldin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.